Department of Vascular Surgery, Zhongshan Hospital (Xiamen) Fudan University, Xiamen, China.
Department of Vascular Surgery, Zhongshan Hospital Fudan University, Shanghai, China.
Vascular. 2024 Jun;32(3):483-489. doi: 10.1177/17085381231153695. Epub 2023 Jan 23.
The aim of this study was to report the long-term outcomes of proximal thoracic endovascular aortic repair (TEVAR) for chronic Stanford type B aortic dissection (cTBAD).
We retrospectively analyzed the clinical data of 48 cases of patients with cTBAD who underwent proximal TEVAR in Zhongshan Hospital Fudan University from January 2010 to September 2013. The preoperative and postoperative imaging examinations, overall survival rate, aortic-related survival rate, and freedom from reintervention rate data were collected to evaluate aortic remodeling and clinical outcomes. The enrolled patients received follow-up at 1, 3, 6, and 12 months following treatment and annually thereafter.
A total of 48 patients (mean age, 58.3 ± 10.6 years; men:women, 40:8) were included, of which 38 cases (79.2%) were uncomplicated dissection and 10 cases (20.8%) were complicated. The mean follow-up time was 48.7 ± 40 months (1-120 months). The mean time interval from the initial procedure to reintervention was 50.6 ± 32.7 months (11-98 months). The following changes were observed at preoperative versus last follow-up timepoints. Descending aortic level: true lumen, 19.2 ± 7.01 mm vs. 36.9 ± 9.53 mm ( < 0.001); false lumen, 30.47 ± 15.89 mm vs. 19.16 ± 15.33 mm ( < 0.001); maximum diameter, 49.67 ± 13.96 mm vs. 56.66 ± 14.95 mm ( = 0.018). Diaphragm level: true lumen, 16.24 ± 5.41 mm vs. 24.41 ± 8.04 mm ( < 0.001); false lumen, 12.37 ± 11.49 mm vs. 14.92 ± 12.25 mm ( = 0.196); and maximum diameter, 34 ± 7.81 mm vs. 38.04 ± 7.7 mm ( < 0.001). The freedom from reintervention rate was 81% in 5 years and 50.6% in 10 years. The overall 10-years survival rate was 83% (6 of 48), and the aortic-related survival rate was 92.3% (3 of 48).
TEVAR is a safe and effective proximal repair intervention for cTBAD that can reliably induce the positive remodeling of the descending aorta.
本研究旨在报告慢性 Stanford 型 B 型主动脉夹层(cTBAD)患者行近端胸主动脉腔内修复术(TEVAR)的长期结果。
我们回顾性分析了 2010 年 1 月至 2013 年 9 月期间在复旦大学中山医院接受近端 TEVAR 的 48 例 cTBAD 患者的临床资料。收集术前和术后影像学检查、总体生存率、主动脉相关生存率和免于再次干预率数据,以评估主动脉重塑和临床结果。纳入的患者在治疗后 1、3、6 和 12 个月以及此后每年进行随访。
共纳入 48 例患者(平均年龄 58.3 ± 10.6 岁;男:女为 40:8),其中 38 例(79.2%)为单纯夹层,10 例(20.8%)为复杂夹层。平均随访时间为 48.7 ± 40 个月(1-120 个月)。初次手术至再次干预的平均时间间隔为 50.6 ± 32.7 个月(11-98 个月)。与术前相比,最后一次随访时观察到以下变化。降主动脉水平:真腔,19.2 ± 7.01mm 比 36.9 ± 9.53mm(<0.001);假腔,30.47 ± 15.89mm 比 19.16 ± 15.33mm(<0.001);最大直径,49.67 ± 13.96mm 比 56.66 ± 14.95mm(=0.018)。膈肌水平:真腔,16.24 ± 5.41mm 比 24.41 ± 8.04mm(<0.001);假腔,12.37 ± 11.49mm 比 14.92 ± 12.25mm(=0.196);最大直径,34 ± 7.81mm 比 38.04 ± 7.7mm(<0.001)。5 年内免于再次干预的比例为 81%,10 年内为 50.6%。总体 10 年生存率为 83%(48 例中的 6 例),主动脉相关生存率为 92.3%(48 例中的 3 例)。
TEVAR 是治疗 cTBAD 的一种安全有效的近端修复干预措施,可可靠地诱导降主动脉的正向重塑。